NCT00368979已完成3 期
Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 378
- 试验地点
- 1
- 主要终点
- Change From Baseline in International Prostate Symptom Score (IPSS) at Week 52
研究概览
简要总结
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Only subjects who meet all the following criteria during the screening phase will be enrolled in the study.
- •Diagnosis: BPH
- •Age: ≥50 years
- •Gender: Male
- •Estimated prostate volume ≥30cc (by TRUS)
- •I-PSS Symptom Score (total of 7 items) ≥8 points
- •Maximum flow rate (Qmax) ≤15mL/sec (voided volume measured simultaneously ≤150mL)*[1]
- •Patients who meet either of the following regarding tamsulosin HCl use:
- •Patients with tamsulosin HCl use:
- •Patients who have received tamsulosin HCl continuously for at least 4 weeks and who are likely to continue to take tamsulosin HCl without any change to the dosage and administration of the drug until the end of study treatment.
- •Patients without tamsulosin HCl use:
- •Patients who haven't received tamsulosin HCl in the past 4 weeks and who are unlikely to use tamsulosin HCl until the end of study treatment.
- •Outpatients
- •Patients who in person have given written consent
排除标准
- •Patients who apply to any of the following criteria during the screening phase will not be enrolled in the study.
- •Post void residual volume >250mL (by suprapubic ultrasound).
- •History of AUR within the previous 12 weeks.
- •Evidence or history of prostate cancer.
- •PSA >10ng/mL [in patients with PSA >4ng/mL, the presence of prostate cancer should be ruled out by the investigator/subinvestigator. DRE and free/total PSA ratio should be considered, and prostate biopsy be conducted if necessary].
- •Previous surgery (including balloon dilatation, thermotherapy and stent placement) or minimally invasive techniques for BPH.
- •Any causes other than BPH, which may in the judgment of the investigator/subinvestigator, affect evaluation of symptoms or urine flow (e.g., neurogenic bladder, bladder neck contracture, urethral stricture, bladder malignancy, acute/chronic prostatitis, acute/chronic urinary tract infection).
- •History of any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias*[2], congestive heart failure or cerebrovascular accident within the previous 6 months; or diabetes mellitus or peptic ulcer uncontrollable with medical treatment.
- •Liver function tests (AST, ALT, AL-P) >2 times the upper limit of normal.
- •Serum cleatinine >1.8mg/dL.
- •Use of any antiandrogen (e.g., chlormadinone acetate, allylesterenol) for BPH within the previous 12 months.
- •Use of a1-adrenoceptor blockers excluding tamsulosin HCl (e.g., prazosin HCl, urapidil slow-release capsule formulation, terazosin HCl, naftopidil), plant extract preparations for treatment of BPH (e.g., Eviprostat, cernitin pollen extract), herbal medicines (e.g., hachimi-jio-gan, gosha-jinki-gan), other drugs (e.g., Paraprost), and dietary or herbal supplements (e.g., saw palmetto) for relief of BPH symptoms within the previous 4 weeks.
- •Use of a-adrenoceptor agonists (e.g., pseudoephedrine, phenyle
- •[1] Subjects with voided volume <150 mL at Qmax measurement cannot be enrolled in the study and may undergo re-measurement of Qmax before the visit for Week 0 for study entry.
- •[2] Of "Degree II" according to "Grading of Side Effects (PMSB Notification No. 80 dated June 29, 1992) or equivalent (Appendix 4).
研究组 & 干预措施
Dutasteride
Active Comparator
干预措施: Dutasteride (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in International Prostate Symptom Score (IPSS) at Week 52
时间窗: Baseline and Week 52
The International Prostate Symptom Score (I-PSS) consists of 7 verified questions concerning urinary symptoms and one quality of life question scored from 0 to 5(0=Not at All, to 5=Almost Always). The total score can range from 0 to 35. Score of 1-7=Mild, 8-19=Moderate, 20-35=Severe.
次要结局
- Number of Participants With Qmax Improvement From Baseline at Week 52(Baseline and Week 52)
- Percent Change From Baseline in Prostate Volume at Week 52(Baseline and Week 52)
- Number of Participants With IPSS Improvement From Baseline at Week 52(Baseline and Week 52)
- Change From Baseline in Maximum Urine Flow Rate (Qmax) at Week 52(Baseline and Week 52)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT00701779Siami, Paul F., M.D.63
已完成
不适用
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASISProstatic HyperplasiaNCT00316732GlaxoSmithKline173
已完成
不适用
Drug Use Investigation for AVOLVE(BPH)Prostatic HyperplasiaNCT01376284GlaxoSmithKline1,000
已完成
3 期
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic AlopeciaAlopeciaNCT00441116GlaxoSmithKline153
已完成
不适用
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)Benign Prostatic HypertrophyNCT00382356North Florida/South Georgia Veterans Health System20